p. 409−415
2251-726X
Vol.27/No.6
p. 417−422
2251-726X
Vol.27/No.6
p. 423−428
2251-726X
Vol.27/No.6
p. 429−434
2251-726X
Vol.27/No.6
p. 435−451
2251-726X
Vol.27/No.6
75% choanal obstruction on primary nasal endoscopy were recruited in this randomized, placebo-controlled trial and randomly divided into two groups. The study group was treated with montelukast 5 mg daily for 12 weeks while the control group received matching placebo for the same period of time. A questionnaire was completed by each child’s parent/guardian to assess the severity of sleep discomfort, snoring, and mouth breathing before and after the intervention.
Results: Adenoid size decreased in 76% of the study group compared with 3% of the placebo group after 12 weeks. A statically significant improvement was observed in the study group compared with the placebo group in terms of sleep discomfort, snoring, and mouth breathing. The symptoms average total score dropped from 7.7 to 3.3 in the study group, while in the placebo group the total score changed from 7.4 to 6.7.
Conclusion: Montelukast chewable tablets achieved a significant reduction in adenoid size and improved the related clinical symptoms of AH and can therefore be considered an effective alternative to surgical treatment in children with adenoid hypertrophy.]]>
p. 453−458
2251-726X
Vol.27/No.6
p. 459−467
2251-726X
Vol.27/No.6
p. 469−472
2251-726X
Vol.27/No.6
p. 473−477
2251-726X
Vol.27/No.6
p. 479−484
2251-726X
Vol.27/No.6
p. 485−489
2251-726X
Vol.27/No.6
p. 491−491
2251-726X
Vol.27/No.6